Rekvina Laboratories
34.30
0.00(0.00%)
Market Cap₹20.70 Cr
PE Ratio-81.67
IndustryHealthcare
Company Performance:
1D0.00%
1M-22.49%
6M+384.46%
1Y+384.46%
5Y+852.78%
View Company Insightsright
More news about Rekvina Laboratories
25Mar 26
Rekvina Laboratories Open Offer: Detailed Public Statement Published for 26% Stake Acquisition
Three acquirers have published a detailed public statement for their mandatory open offer to acquire 28,90,100 equity shares (26% stake) of Rekvina Laboratories at ₹10 per share, following a share swap agreement to acquire Radiant Parenterals. The offer involves ₹2,89,01,000 consideration with escrow arrangements in place and is scheduled to run from May 14-27, 2026.
 no imag found
18Mar 26
Rekvina Laboratories Schedules EGM for April 10 to Approve Capital Restructuring
Rekvina Laboratories has formally notified shareholders of an extraordinary general meeting on April 10, 2026, to vote on increasing authorized share capital from ₹3.50 crore to ₹6 crore, acquiring 100% stake in Radiant Parenterals for ₹4.62 crore through share exchange, and issuing additional equity shares for cash consideration.
 no imag found
17Mar 26
Rekvina Laboratories Discloses Open Offer Public Announcement to BSE
Rekvina Laboratories Limited has formally disclosed to BSE Limited the receipt of a public announcement for an open offer by three acquirers - Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel. The offer seeks to acquire 28,90,100 equity shares at ₹10 per share, representing 26% of expanded share capital with total consideration of ₹2,89,01,000. The transaction was triggered by a share exchange agreement for acquiring Radiant Parenterals Limited, managed by Vivro Financial Services under SEBI regulations.
 no imag found
1 Year Returns:+384.46%
Industry Peers
Sun Pharmaceutical
1,870.50
(+0.43%)
Divis Laboratories
6,574.00
(-0.08%)
Torrent Pharmaceuticals
4,606.00
(-0.31%)
Cipla
1,448.90
(-1.13%)
Dr Reddys Laboratories
1,344.20
(-0.95%)
Zydus Life Science
1,110.10
(-0.22%)
Lupin
2,400.10
(-0.78%)
Mankind Pharma
2,508.90
(-1.44%)
Aurobindo Pharma
1,554.60
(-1.53%)
Laurus Labs
1,495.50
(-1.44%)